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Abstract
Background: Permanent cardiac pacing is a known method of the treatment for children
with bradycardia. Epicardial pacing is required in small children and in children with some
congenital heart defects. Steroid-eluting leads (SEL) have been introduced to reduce implant
site fibrosis and to retain permanent low-pacing threshold values. Our aim was to evaluate the
pacing characteristic and follow-up of children with epicardial steroid-eluting pacing.
Material and methods: We implanted steroid-eluting epicardial pacing systems in 53 chil-
dren (age at implantation: 2 days – 17.5 years, mean 4.6 years), of whom 37 (70%) had
congenital heart disease and 22 of these had already had cardiac surgery. These children
formed group I. Group II was the control group and consisted of 29 children (age at implanta-
tion: 10 days – 13 years, mean 6.5 years) with non-steroid epicardial pacing systems; 15 patients
(51%) had diagnosed congenital heart disease, and 9 of these had had cardiac surgery. The
pacing threshold (PT) was obtained during implantation, before discharge, 1–3 and 6 months
following implantation and then every 6 months.
Results: In group I the mean PT during the implantation procedure was 1.6 V/0.4 ms and
decreased significantly before discharge. In group II the PT during the implantation procedure
was low and increased before discharge. In group I the PT of the atrial leads was low and
stable during the follow-up period, while the PT of the ventricular leads slowly increased and
four years following implantation was similar to that of group II.
Conclusions: In children with permanent epicardial pacing the ventricular PT was signifi-
cantly lower when steroid-eluting leads had been used then when these had not been used, but
during the follow-up period the PT slowly increased, while the pacing threshold of atrial
steroid-eluting leads remained stable. (Folia Cardiol. 2006; 13: 312–318)
permanent cardiac pacing, children, epicardial steroid-eluting electrodes
Introduction
The first pacemaker implantation in a child took
place in 1962. Since then this has been a recogni-
sed treatment in children with bradyarrhythmia.
The technological development of both pacemakers
and leads has contributed to a higher proportion of
children receiving implants and to higher accessi-
bility of the method even for the youngest children.
313
Monika Brzezinska-Paszke et al., Epicardial pacing in children
www.fc.viamedica.pl
At first epicardial stimulation was used in children,
because the available endocardial leads were too
clumsy. It was later discovered that this method of
cardiac pacing had numerous complications. Implan-
tation of an epicardial pacemaker system is a more
invasive procedure than implantation of an endocar-
dial one. It is performed by a surgeon or cardiosur-
geon under general anaesthesia. When access has
been gained to the heart the leads are stitched on,
the heart, which sometimes causes post-pericardio-
tomy syndrome and increases the risk of further
complications, such as unintended pleura piercing.
An increase in the pacing threshold (PT) is often
observed, resulting from tissue fibrosis and scar-
ring around the lead. As a result, programming of
a higher impulse amplitude and/or width is needed,
which leads to shortening of the pacemaker’s life.
Sometimes the PT is so high that it makes heart
stimulation impossible (exit block). A replacement
of the implanted pacemaker system is then needed.
Positive experience from endocardial pacing in
adults and ongoing progress in the method has
made usage of this method in very young children
increasingly popular. However, there are still pa-
tients with indications for epicardial pacing (EP),
including low body weight, intracardial septal de-
fects (risk of thrombosis), venal defects or obstruc-
tions and operated complex congenital heart de-
fects (CHD) making implantation of the endocar-
dial leads impossible (for example hearts after
Fontan operation).
Epicardial steroid-eluting leads, introduced in
the mid-1980s, have contributed to a lowering of the
PT through a decrease in inflammation in the area
where the lead touches the heart [1–13].
The aim of the study was to monitor the pa-
cing parameters in children with EP with steroid-
eluting leads (SEL).
Material and methods
Between May 1989 and June 2004 we monito-
red 82 patients of the Department of Cardiology of
The Children’s Memorial Health Institute (CMHI)
with epicardial pacing systems. Group I included 53
children (27 female, 26 male) with EP with SEL
(available from 1996). Group II (the control group)
was made up of 29 children (17 female, 12 male)
with non-SEL EP. The possibility of a comparison
of the monitored stimulation parameters across the
groups was an additional criterion for selection to
the control group. Of all our patients without SEL
EP we chose those whose impulse width was simi-
lar to that of our SEL EP patients. All the children
were thoroughly examined, underwent ECG, chest
X-ray, echo and Holter ECG. Heart catheterisation
was also performed where needed.
The implantation of the EP was performed by
a cardiosurgeon with the patients under general
anaesthesia. The leads were stitched to the heart,
while the pacemaker was usually placed under the
left rib arch.  In a few cases the epicardial leads were
stitched during cardiosurgical correction of conge-
nital heart disease. The children were observed
during the postoperative period and any complica-
tions were examined. The PT was measured during
the implantation using an ERA 300 Biotronic pro-
grammer. The PT was then measured before di-
scharge from the hospital, 1–2 months after implan-
tation and every 6 months thereafter with the use
of a programmer relevant to the pacemaker (Med-
tronic or St. Jude Medical). The pacing parameters
were analysed retrospectively and prospectively.
The patients were monitored until they reached
maturity or the EP system was replaced.
For statistical purposes Student’s t tests were
run using Microsoft Excel.
Results
Group I
Group I was made up of 53 children. The age
of the patients during implantation of the EP with
SEL ranged from 2 days to 17.5 years (average: 4.6 yrs).
The indications for pacemaker implantation are pre-
sented in Table 1.
For 44 patients EP with SEL was the first sys-
tem implanted. Nine children had previously had
a pacemaker: three had had an endocardial pacema-
ker and six had had an epicardial one without SEL.
One patient had the EP with SEL implanted for the
third time.
In 33 cases single-lead epicardial stimulation
was applied (28 VVIR and 5 VVI), 20 patients had
double-lead systems implanted (12 DDD, 7 DDDR,
1 DDI). In total 73 SEL were implanted in 53 chil-
dren, including 53 ventricular and 20 atrial leads.
All leads were manufactured by Medtronic (10366,
4965 and 4968). The PT of ventricular leads during
implantation ranged from 0.5 to 5 V with an avera-
ge of 1.6 V and an impulse width of 0.4 ms. In 8 ca-
ses PT amplitude was higher than 2 V for a few mi-
nutes after implantation (6 patients had had conge-
nital heart disease correction while two had
myocarditis) but decreased spontaneously after
a short time. The PT of atrial leads during implanta-
tion ranged from 0.4 to 3 V with an average of 1.6 V,
impulse width 0.4 ms.
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In 24 patients (45.3%) no complications were
witnessed during the operation or the early posto-
perative period. One patient had a short episode of
ventricular tachycardia while the leads were being
stitched. In 7 cases non-effective stimulation was
observed over some minutes following implantation
as a result of a high PT (up to 5 V); subsequent
measurements showed a rapid decrease in PT.
A total of 14 patients (26.4%) suffered an exudation
in the pericardium during the first few days after
EP implantation and of these ten required drainage
of the pericardium. In two cases spontaneous su-
praventricular tachycardia occurred shortly after
implantation, which required anti-arrhythmic drug
treatment (both patients had had episodes of this
supraventricular tachycardia before the operation).
In two neonates the pacemakers dislocated into the
pleura: in one of these patients the pacemaker was
repositioned under the rib arch. In one child with
a postoperative complete heart block (CHB) after
correction of a ventricular septal defect (VSD) and
atrial septal defect (ASD) a rapid increase in PT was
observed. This child had to have the pacemaker
replaced with an endocardial one.
Despite correct pacing two neonates with CHB
and complex congenital heart disease died soon after
the pacemaker implantation. One of the patients had
a Blallock-Taussig shunt. The second had had aortic
valvuloplasty. In both cases increasing symptoms of
heart and internal organ failure were observed.
The measurement of PT at discharge from the
hospital (on average on the 7th day after the opera-
tion) showed a significant decrease in the PT of the
ventricular leads, ranging from 0.4 to 4.5 V, with
an average of 1.1 V (impulse width 0.4 ms). The PT
of the atrial leads dropped by 0.2–1 V, with an ave-
rage of 0.53 V (impulse width 0.4 ms). The diffe-
rences between PT during implantation and PT at
discharge were statistically significant (p < 0.01).
The observation period of patients with EP
with SEL ranged from one week (early postopera-
tive deaths) to 7.3 years, with an average of 2.5
years. Three patients died within 4 months of le-
aving the hospital. These had complex CHD and
increasing symptoms of heart failure despite cor-
rect cardiac pacing.
The average PT amplitude values (at an impul-
se width of 0.4 ms) subsequently measured in our
patients are presented in Figure 1. The PT of the
atrial leads was stable in the observation period,
while the PT of the ventricular leads gradually in-
creased from the second year after implantation.
During the observation period 6 patients requ-
ired replacement of the EP with SEL. In one case
the reason for the replacement was a gradual incre-
ase in the PT of the ventricular lead; in this case
only the atrial lead was left. In 5 patients defects
were discovered in one or both leads between
21 and 70 months following implantation. In two of
these cases the pacemaker was reprogrammed on
VVIR, while in two other children the EP system
Table 1. Indications for implantation of an epicar-
dial pacemaker system and CHD in group I
Indications for Congenital
implantation of EP heart defect
Postoperative CHB — 18 AVSD — 3
AVSD, TAPVD — 1
VSD — 3
VSD, ASD — 1
VSD, ASD, PDA — 2
CTGA, VSD — 2
TGA — 1
TGA, VSD, ASD, PS — 1
DILV, ASD, PDA — 1
DILV, TGA, CoA, PDA — 1
ToF, PVA — 1
SAS — 1
Postoperative, AVSD — 1
paroxysmal CHB — 2 DORV, PS — 1
Postoperative sinus TGA, DORV, PS, AVSD — 1
node dysfunction — 2 TGA, AT, PS, ASD, PDA — 1
Congenital CHB — 20 No CHD — 10
SV, SA — 1
ASD — 2
ASD, PDA — 1
VSD — 1
CTGA — 2
SV — 2
CTGA, VSD — 1
Paroxysmal CHB — 2 VSD, ASD — 1
ASD — 1
Congenital sinus DILV, PS — 1
node dysfunction — 2 ASD — 1
Postinflammatory CHB — 5 No CHD — 5
Postinflammatory sinus ASD, PDA, PS — 1
node dysfunction — 2 No CHD — 1
EP — epicardial pacemaker; CHB — complete heart block;
CHD — congenital heart defect; ASD — atrial septal defect;
VSD — ventricular septal defect; AVSD — atrioventricular septal defect;
ToF — tetralogy of Fallot; TGA — transposition of great vessels;
CTGA — corrected transposition of great vessels; DILV — double
inlet left ventricle; DORV — double outlet right ventricle; SV — single
ventricle; SA — single atrium; PS — pulmonary valve stenosis;
SAS — supravalvular aortic valve stenosis; PDA — persistent ductus
arteriosus; TAPVD — total anomalous pulmonary vein drainage;
PVA — pulmonary valve atresia; CoA — coarctation of aorta
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was replaced with an endocardial one and one pa-
tient had another EP system with SEL implanted.
In two patients pacemakers were replaced becau-
se of battery depletion: after one year in one child
with fibroelastosis and long QT syndrome who had
a high PT and in another after 5 years.
At present 43 children from Group I are moni-
tored by the Department of Cardiology of CMHI.
A total of 39 patients (73.6%) still have their first
EP systems with SEL, three  patients had reached
adult age and one child is under the supervision of
the Cardiological Outpatient Clinic in Zabrze. One
patient has had a heart transplantation and does not
require cardiac pacing. The physical development
and condition of our patients and of those who are
now adults is good.
Group II
Group II included 29 children (17 female and
12 male). The patient’s age at implantation of the
EP system without SEL ranged from 10 days to
13 years, with an average of 6.5 yrs). The pacemaker
implantation indications are presented in Table 2.
For 24 patients EP without SEL was the first
implanted system. Five children had previously had
a pacemaker: four had had an endocardial pacema-
ker and one had had an epicardial one without SEL.
In these 5 children the reason for implanting a new
pacemaker system was lead damage.
Table 2. Indications for implantation of epicardial
pacemaker system and CHD in group II
Indications for Congenital
implanting EP heart defect
Postoperative CHB — 7 AVSD — 2
VSD — 2
ASD, PS — 1
ToF — 1
TGA, VSD — 1
Postoperative, VSD — 1
paroxysmal CHB — 1
Postoperative sinus TGA after SO — 1
node dysfunction — 1
Congenital CHB — 18 No CHD — 13
(with LQTS — 2) CTGA — 2
SV, TGA — 1
SV, ASD, PS — 1
ASD — 1
Congenital sinus ASD — 1
node dysfunction — 1
LQTS — 1 No CHD — 1
EP — epicardial pacemaker; CHB — complete heart block;
CHD — congenital heart defect; ASD — atrial septal defect;
VSD — ventricular septal defect; AVSD — atrioventricular septal
defect; ToF — tetralogy of Fallot; TGA — transposition of great
vessels; CTGA — corrected transposition of great vessels;
SV — single ventricle; PS — pulmonary valve stenosis;
LQTS — long QT syndrome; SO — Senning operation
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Figure 1. Changes in the pacing threshold (PT) of atrial (A) and ventricular (V) steroid-eluting (SE) leads and
ventricular non-steroid leads (NSE) during the follow-up period.
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In all cases single-lead epicardial stimulation
was applied (21 VVI and 8 VVIR). The leads implan-
ted were manufactured by Biotronic (in 22 patients),
CPI (6 patients) and Siemens (1 child). PT during
implantation ranged from 0.3 to 2.4 V, with an ave-
rage of 1.2 V (impulse width 0.4 ms).
In 12 patients (41%) no complications were
observed during the operation or the early posto-
perative period. A total of 9 patients (31%) suffe-
red from an exudation in the pericardium and of
these two required pericardium drainage. Delayed
healing of the surgical wound was observed in two
children and one child had intermittent fever. Other
complications (pleural effusion, brain ischaemia and
inflammation of the sternum) were due to cardio-
surgical correction of CHD.
The measurement of the PT at discharge from
the hospital (on average on the 7th day after the
operation) showed a significant increase in PT, ran-
ging from 0.8 to 2.8 V, with an average of 1.7 V (im-
pulse width 0.4 ms). The differences between PT
during implantation and PT at discharge were sta-
tistically significant (p < 0.01).
The observation period of patients in group II
ranged from two months (lead damage) to
15 years, with an average of 7.7 years. Two patients
have died: one, a female with complex CHD (sin-
gle ventricle and subvalvular pulmonary stenosis
with CHB), two months after the EP system implan-
tation and the second, a girl who had fibroelastosis
and LQTS, three months after implantation. Both
cases showed increasing symptoms of heart failu-
re, although their cardiac pacing was correct.
The average PT amplitude values (impulse
width 0.4 ms) subsequently measured are presen-
ted in Figure 1. During the follow-up period the PT
increased gradually in the first 6 months after im-
plantation and then stabilised.
During the observation period 6 patients requ-
ired EP system replacement. The procedures were
performed between two months (because of lead
damage) and 11 years (change for an endocardial
pacing system) after implantation (at a mean
3.8 years). In 4 children the EP system was replaced
by an endocardial one. Two patients had another EP
system implanted but with SEL. Three patients
required a new pacemaker system because of lead
damage; in one child the pacing system was repla-
ced during cardiosurgical correction of CHD. A to-
tal of 6 children required pacemaker replacement
because of battery depletion (3.5 to 7 years after
implantation, at a mean of 5.5 years).
At present 11 children from Group II are still
our patients, 15 patients have reached adult age.
Eighteen patients have their first EP system. One
patient has gone abroad and so far we have rece-
ived no information about her. The physical deve-
lopment and condition of our patients, as well as of
those who have reached adulthood, is good.
The amplitudes (the impulse duration remaining
constant at 0.4 ms) of the PT measured in the two
groups were compared. Patients with EP and SEL
had a lower PT amplitude during pacing system im-
plantation and the two subsequent years than pa-
tients who did not receive SEL. The differences were
statistically significant (p < 0.04). During the third
and fourth year after pacemaker implantation this dif-
ference gradually decreased and after four years PT
was much the same in children with and without SEL.
Discussion
In the first years of heart pacing epicardial le-
ads were commonly used in children. It soon beca-
me apparent that numerous problems arise when
using EP. In 20–30% of patients an increase in TP
is observed, which requires programming of
a higher amplitude and/or higher impulse width.
This leads to faster battery depletion and pacema-
ker replacement. Lack of correct pacing (exit block)
requires replacement of the implanted pacing sys-
tem. Because of these problems endocardial pacing
systems were increasingly used even in the youn-
gest children. However, EP is needed by patients
with low body weight, intracardial septal defects,
venal anomalies or obstruction or complex conge-
nital heart defects, making implantation of the en-
docardial lead impossible. The introduction of SEL
has contributed to a wider usage of EP. It has tur-
ned out that pacing parameters with the use of SEL
are significantly better for a longer period of time
than when non-steroid EP is used and are compa-
rable to endocardial pacing parameters [13–15].
In Group I the PT during implantation was hi-
gher than described by other authors, although it
dropped quickly and significantly after an average
of 7 days, which was comparable to cases descri-
bed in other papers. Usage of different pacing pro-
grammers may explain the difference in PT values
referred to above. In our patients the PT of the atrial
leads did not change significantly during the follow-
up period, while ventricular lead PT started to rise
gradually after two years of observation. Similar
differences in lead parameters were observed by
Johns and others within one year of implantation.
However, other authors have written that the ven-
tricular and atrial PT was stable and low for years,
although there were also cases of increasing PT and
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exit block in children with SEL [14–16]. This later
problem also affected two of our patients.
In this paper we have compared the clinical
course of EP in two groups, similar in indications
of pacemaker implantation and heart diseases.
In both groups the method’s complications and their
frequency are in line with the findings reported in
other medical papers [14–20]. In the early posto-
perative period patients can suffer from exudation
in the pericardium. This was observed in
23 (28%) of our patients. The most common cause
of pacemaker system change in our patients, and in
the cases described by other authors, is lead dama-
ge. A case of dislocation of the pacemaker to the
chest, as occurred in two of our youngest patients,
has also been described [21].
Children with SEL had a low PT in the first
years after their operation, which is in line with
numerous reports in the literature [13, 22–25].
After an average period of 4 years the pacing para-
meters of the ventricular leads were similar in the
two groups, those with and those without steroid-
eluting leads. Despite the rise in PT found in Gro-
up I, 4 years of low PT is a significant advantage for
our patients. In addition, using pacemakers with an
autocapture function in the youngest patients pro-
longs the battery life and delays its replacement.
The high quality of steroid-eluting leads and
their parameters have encouraged their widespre-
ad usage in children. The implantation of an EP
system with SEL as the first one in the youngest
patients, even when the use of endocardial pacing
is possible, is considered a preferable way of pro-
ceeding in many hospitals. This should have a po-
sitive impact on children’s developing blood ves-
sels. Stitching of the lead in a place avoiding the
right ventricle apex is equally important.
Children with permanent cardiac pacing need
this treatment throughout their lives.  Maximising
the duration of correct pacing should be the main
goal. This can be achieved by the use of top quality
leads and pacemakers, allowing the child to lead
a normal active life. The pacemakers with long-life
batteries and the autocapture function should be used
more often. Post-implantation systematic monitoring
of a patient is also important [1, 4, 9–12, 26–29].
Conclusions
1. The pacing thresholds of children with epicar-
dial pacing and steroid-eluting leads are signi-
ficantly lower then those of patients with non-
steroid-eluting leads.
2. The pacing threshold of ventricular steroid-
eluting leads increases throughout the seve-
ral years of follow-up, while the pacing thre-
shold of atrial steroid-eluting leads remains
stable.
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